Los Angeles Capital Management
ACHN

Los Angeles Capital Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Los Angeles Capital Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-130,000
Closed -$597K – 1381
2017
Q2 		$597K Buy
+130,000
New +$523K ﹤0.01% 896

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Los Angeles Capital Management's ACHN Position: Q3 2017 in Review

Los Angeles Capital Management sold out of Achillion Pharmaceuticals (ACHN) in Q3 2017, closing a stake of 130,000 shares — an estimated $597K sold.

Los Angeles Capital Management first reported a position in ACHN in Q2 2017 and held it in 1 quarter. The position peaked at $597K in Q2 2017. 125 funds tracked by Wall St. Rank hold ACHN as of Q3 2017.

  • Los Angeles Capital Management reported no remaining Achillion Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Los Angeles Capital Management sold 130,000 Achillion Pharmaceuticals shares in Q3 2017, an estimated $597K.
  • Los Angeles Capital Management first reported a position in Achillion Pharmaceuticals in Q2 2017 and held it in 1 quarter.
  • Los Angeles Capital Management's Achillion Pharmaceuticals position peaked at $597K in Q2 2017.
  • 125 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2017.

Based on Los Angeles Capital Management's 13F filing for Q3 2017, filed 6 Nov 2017.